Genvoya and Stribild are both four-drug, antiviral combinations containing elvitegravir, cobicistat, emtricitabine, and tenofovir indicated as complete regimens for the treatment of HIV-1 infection.

The difference between Genvoya and Stribild is in the form of tenofovir contained in each product.

Genvoya contains a newer form of tenofovir called tenofovir alafenamide (TAF) and Stribild contains the original form of tenofovir as tenofovir disoproxil fumarate (TDF).

Tenofovir alafenamide is a prodrug of tenofovir that has been designed to enter HIV-infected cells more efficiently than TDF, and it can therefore be given at a much lower dose (less than one-tenth) than TDF. TAF appears to be associated with less kidney toxicity and decreases in bone density compared to TDF.

The dose for both Genvoya and Stribild is one tablet taken orally once daily with food.

Genvoya and Stribild are both manufactured by Gilead Sciences Inc.